BioSpace News Archive

Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glyco-Immune Checkpoint inhibitors to treat cancer.

BioLife Solutions is a leading supplier of class-defining cell and gene therapy bioproduction tools and services. Our tools portfolio includes our proprietary CryoStor® and HypoThermosol® biopreservation media for shipping and storage, the ThawSTAR® family of automated, water-free thawing products, evo® cold chain management system, high capacity cryogenic storage freezers, Stirling Ultracold mechanical freezers, SciSafe biologic storage services, and Sexton Biotechnologies cell processing tools.

Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases.

Hexagon Bio is a data-driven biopharma company developing targeted small molecule therapeutics. Our proprietary platform combines data science, genomics, synthetic biology, chemistry and automation to discover potent, evolutionarily-refined small molecules and their cognate targets directly from DNA sequences.

Cell Microsystems’ transformative platforms for cell engineering, culture, and analysis empower laboratories worldwide to unlock the full potential of their cells, making what was once impossible possible.

Epic Bio is a biotechnology company developing ultracompact therapies to modulate gene expression in vivo using the smallest known Cas protein, CasMINI.

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise.

Rheos Medicines, Inc. is no longer in business.

Ambys Medicines is focused on unlocking the full potential of hepatocyte transplantation and transforming the treatment of severe liver disease. Ambys’ proprietary cell therapy platform potentially solves the supply constraints that have hindered progress, catalyzing the field and fundamentally transforming the approach to treating severe liver disease.

Vielo Bio was acquired by Horizon Therapeutics in 2021.